CO2022009246A2 - Anticuerpo anti-c5 para el tratamiento del trastorno del espectro de la neuromielitis óptica - Google Patents
Anticuerpo anti-c5 para el tratamiento del trastorno del espectro de la neuromielitis ópticaInfo
- Publication number
- CO2022009246A2 CO2022009246A2 CONC2022/0009246A CO2022009246A CO2022009246A2 CO 2022009246 A2 CO2022009246 A2 CO 2022009246A2 CO 2022009246 A CO2022009246 A CO 2022009246A CO 2022009246 A2 CO2022009246 A2 CO 2022009246A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody
- treatment
- spectrum disorder
- neuromyelitis optica
- optica spectrum
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
ANTICUERPO ANTI-C5 PARA EL TRATAMIENTO DEL TRASTORNO DEL ESPECTRO DE LA NEUROMIELITIS ÓPTICA RESUMEN Se proporcionan métodos para el tratamiento clínico del trastorno del espectro de la neuromielitis óptica (NMOSD) utilizando un anticuerpo anti-C5 o un fragmento de unión a antígeno del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962945644P | 2019-12-09 | 2019-12-09 | |
PCT/US2020/063781 WO2021118999A1 (en) | 2019-12-09 | 2020-12-08 | Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022009246A2 true CO2022009246A2 (es) | 2022-07-29 |
Family
ID=74046204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0009246A CO2022009246A2 (es) | 2019-12-09 | 2022-07-01 | Anticuerpo anti-c5 para el tratamiento del trastorno del espectro de la neuromielitis óptica |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230043034A1 (es) |
EP (1) | EP4073110A1 (es) |
JP (1) | JP2023504209A (es) |
KR (1) | KR20220110827A (es) |
CN (1) | CN114867747A (es) |
AU (1) | AU2020401102A1 (es) |
BR (1) | BR112022011280A2 (es) |
CA (1) | CA3161271A1 (es) |
CO (1) | CO2022009246A2 (es) |
MX (1) | MX2022007116A (es) |
WO (1) | WO2021118999A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023215443A1 (en) * | 2022-05-04 | 2023-11-09 | Alexion Pharmaceuticals, Inc. | Compositions and methods for the treatment of neuromyelitis optica spectrum disorder |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
ES2541142T3 (es) | 2008-08-05 | 2015-07-16 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos contra la proteína C5 del complemento |
JO3437B1 (ar) * | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
SI2563813T1 (sl) * | 2010-04-30 | 2015-12-31 | Alexion Pharmaceuticals, Inc. | Protitelesa anti-C5A in postopki uporabe protiteles |
TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
EA201791366A1 (ru) | 2014-12-19 | 2018-02-28 | Чугаи Сейяку Кабусики Кайся | Антитела к c5 и способы их применения |
US20180142010A1 (en) * | 2015-06-26 | 2018-05-24 | Alexion Pharmaceuticals, Inc. | Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
US20190023775A1 (en) * | 2016-01-11 | 2019-01-24 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
MA45235A (fr) | 2016-06-14 | 2019-04-17 | Regeneron Pharma | Anticorps anti-c5 et leurs utilisations |
US11112411B2 (en) * | 2017-03-31 | 2021-09-07 | Alexion Pharmaceuticals, Inc. | Method for simultaneous quantification of ALXN1210 and eculizumab in human serum or urine |
JP2022501378A (ja) * | 2018-09-21 | 2022-01-06 | アレクシオン ファーマシューティカルズ インコーポレイテッドAlexion Pharmaceuticals, Inc. | 視神経脊髄炎の処置のためのエクリズマブ |
-
2020
- 2020-12-08 US US17/783,106 patent/US20230043034A1/en active Pending
- 2020-12-08 KR KR1020227023328A patent/KR20220110827A/ko unknown
- 2020-12-08 CN CN202080085425.0A patent/CN114867747A/zh active Pending
- 2020-12-08 CA CA3161271A patent/CA3161271A1/en active Pending
- 2020-12-08 EP EP20829482.7A patent/EP4073110A1/en active Pending
- 2020-12-08 BR BR112022011280A patent/BR112022011280A2/pt unknown
- 2020-12-08 JP JP2022534708A patent/JP2023504209A/ja active Pending
- 2020-12-08 WO PCT/US2020/063781 patent/WO2021118999A1/en unknown
- 2020-12-08 MX MX2022007116A patent/MX2022007116A/es unknown
- 2020-12-08 AU AU2020401102A patent/AU2020401102A1/en active Pending
-
2022
- 2022-07-01 CO CONC2022/0009246A patent/CO2022009246A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020401102A1 (en) | 2022-07-21 |
MX2022007116A (es) | 2022-07-11 |
CN114867747A (zh) | 2022-08-05 |
KR20220110827A (ko) | 2022-08-09 |
US20230043034A1 (en) | 2023-02-09 |
JP2023504209A (ja) | 2023-02-01 |
EP4073110A1 (en) | 2022-10-19 |
WO2021118999A1 (en) | 2021-06-17 |
CA3161271A1 (en) | 2021-06-17 |
BR112022011280A2 (pt) | 2022-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
CO2020004831A2 (es) | Dosis y administración de anticuerpos antic-c5 para el tratamiento de pacientes con glomerulonefritis membranoproliferativa | |
DOP2020000245A (es) | Anticuerpos il-11 | |
UY36194A (es) | Anticuerpos anti-tau humanizados | |
EA202090641A1 (ru) | Мультиспецифическая антиген-связывающая молекула, обладающая замещающей функциональной активностью кофактора коагулирующего фактора крови viii, и фармацевтическая композиция, содержащая указанную молекулу в качестве активного ингредиента | |
UY36757A (es) | Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada | |
EA201790339A1 (ru) | Комбинированные препараты с антителами к cd40 | |
CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
CO2022009696A2 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
PE20160192A1 (es) | Composiciones y metodo para tratar condiciones asociadas con el complemento | |
CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
CY1123275T1 (el) | Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων | |
EA202192130A1 (ru) | Специфичные к ltbp-комплексу ингибиторы tgf и их применение | |
CU24556B1 (es) | Anticuerpos anti-basigin humanizados | |
PE20230381A1 (es) | Proteina de union a rgma | |
CY1125297T1 (el) | Αναστολεις της il-8 για χρηση στην αγωγη της περιφερικης νευροπαθειας που επαγεται απο χημειοθεραπεια | |
BR112021020924A2 (pt) | Uso de um anticorpo anti-cd19 para tratar doença autoimune | |
CO2017004753A2 (es) | Anticuerpos que se unen a ccr6 | |
CL2021000483A1 (es) | Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide. | |
CO2022009246A2 (es) | Anticuerpo anti-c5 para el tratamiento del trastorno del espectro de la neuromielitis óptica | |
CO2019002550A2 (es) | Anticuerpos anti-gm-csf y usos de los mismos | |
EA201992348A1 (ru) | АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1 | |
EA202191470A1 (ru) | Антитела, специфично распознающие рецептор-альфа гранулоцитарно-макрофагального колониестимулирующего фактора, и их применения | |
CL2022002727A1 (es) | Anticuerpo anti-cd47 y usos del mismo | |
CO2018010286A2 (es) | Método para la purificación de proteínas |